Analgesic Techniques for Rib Fractures
Launched by THOMAS JEFFERSON UNIVERSITY · Jul 19, 2024
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying different ways to relieve pain for adults who have suffered three or more rib fractures. The researchers want to find out which method works best in helping patients manage their pain and recover more effectively. They will compare three techniques: one involves a special nerve block with a medication called ropivacaine, another uses lidocaine (a common numbing medication), and the third is standard care that includes various pain relief medications, including opioids.
To be eligible for this trial, participants need to be at least 55 years old and have sustained three or more rib fractures on one side of their body. The trial is currently recruiting, and each participant can expect to be randomly assigned to one of the three pain relief methods. The study will measure things like how much pain relief they get, how their breathing improves, and whether they need less medication over time. This trial aims to improve how patients recover from rib fractures and reduce the risk of long-term pain after their hospital stay.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ≥ 55 years old
- • Sustained 3 or more unilateral rib fractures and are admitted to the hospital
- Exclusion Criteria:
- • Allergy to amide local anesthetics or any study medications
- • Pregnancy
- • Bilateral rib fractures
- • Coagulopathy (INR \> 1.5; platelets \< 100,000)
- • Conduction block on EKG
- • Spine fracture at the level of intended ESP block
- • Infection near the ESP insertion site or active bacteremia or sepsis
- • Any patient deemed a poor candidate for ESP block and/or lidocaine infusion will also be excluded
About Thomas Jefferson University
Thomas Jefferson University is a distinguished academic institution located in Philadelphia, Pennsylvania, renowned for its commitment to advancing healthcare through research and education. As a clinical trial sponsor, the university leverages its extensive resources and interdisciplinary expertise to conduct innovative research aimed at improving patient outcomes. With a focus on translational medicine, Thomas Jefferson University collaborates with various stakeholders, including healthcare professionals, industry partners, and regulatory agencies, to ensure the highest standards of scientific rigor and ethical conduct in its clinical trials. The institution is dedicated to fostering a culture of excellence in research, ultimately contributing to the advancement of medical knowledge and the development of novel therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Patients applied
Trial Officials
Eric Schwenk, MD
Principal Investigator
Thomas Jefferson University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported